Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM NITROPRUSSIDE vs GONITRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium nitroprusside is a prodrug that releases nitric oxide (NO) in vascular smooth muscle cells, activating guanylate cyclase and increasing c GMP, leading to vasodilation of both arterial and venous vessels.
Nitric oxide (NO) donor; activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation.
Immediate reduction of blood pressure in hypertensive crises,Induction of controlled hypotension during anesthesia,Treatment of acute heart failure (off-label)
Prevention of angina pectoris due to coronary artery disease,Acute relief of angina episodes,Prophylaxis for angina before exertion or stress
Intravenous infusion: Initial 0.3-0.5 mcg/kg/min; titrate up to 10 mcg/kg/min, maximum 10 mcg/kg/min for up to 10 minutes. Usual therapeutic dose: 3 mcg/kg/min. Max cumulative dose: 3.5 mg/kg.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.
Sodium nitroprusside itself has a half-life of approximately 2 minutes (converted to cyanide in erythrocytes); the metabolite thiocyanate has a terminal half-life of 2.7-7 days (prolonged in renal impairment, requiring monitoring)
Terminal elimination half-life approximately 2-3 minutes for nitroglycerin; clinical effects cease within 30-60 minutes due to rapid redistribution and metabolism
Sodium nitroprusside undergoes non-enzymatic degradation in erythrocytes and tissues, releasing cyanide. Cyanide is metabolized by rhodanese (thiosulfate sulfurtransferase) to thiocyanate, primarily in the liver and kidneys.
Extensively metabolized by mitochondrial aldehyde dehydrogenase (ALDH2) in vascular smooth muscle; also metabolized by glutathione S-transferases and cytochrome P450 (CYP3A4).
Renal: approximately 75% as thiocyanate (metabolite) with 25% unchanged; biliary/fecal: minimal (<5%)
Primarily renal: 80-90% as inactive metabolites (dinitrates, mononitrates); minor biliary/fecal (<10%)
Sodium nitroprusside: negligible protein binding (<5%); thiocyanate: weakly bound to plasma proteins (approximately 5%)
60% bound, primarily to plasma albumin
Sodium nitroprusside: approximately 0.2 L/kg (distributes primarily in extracellular fluid); thiocyanate: approximately 0.2-0.3 L/kg (distributes similarly to extracellular water)
Approximately 3.3 L/kg; extensive tissue distribution with high affinity for vascular smooth muscle
Intravenous: 100% (only route of administration); oral: not applicable (no oral bioavailability due to instability and extensive first-pass metabolism)
Sublingual: 40-60%; Oral (immediate-release): <10% due to first-pass hepatic metabolism; Transdermal: 70-90% (drug-in-adhesive); Intravenous: 100%
GFR <60 m L/min: Use with caution; reduce initial dose by 50% and monitor for cyanide toxicity. GFR <30 m L/min: Avoid due to risk of thiocyanate accumulation.
No specific dose adjustment required for renal impairment. However, use with caution in severe renal dysfunction (Cr Cl <30 m L/min) due to increased risk of hypotension and methemoglobinemia.
Child-Pugh Class B: Reduce initial dose by 50% and monitor for cyanide toxicity; maximum infusion rate 2 mcg/kg/min. Child-Pugh Class C: Contraindicated due to risk of severe cyanide toxicity.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 50% due to decreased clearance. Child-Pugh C: Avoid use or use with extreme caution; consider alternative therapy.
Children: Intravenous infusion 0.3-1 mcg/kg/min initially; titrate to effect, not to exceed 10 mcg/kg/min. Neonates: 0.5-1 mcg/kg/min; maximum 5 mcg/kg/min.
Sublingual: 5-10 mcg/kg/dose, maximum 0.3 mg per dose, may repeat every 5 minutes up to 3 doses. Intravenous: Start at 0.25-0.5 mcg/kg/min, titrate up to 1-5 mcg/kg/min based on response. Not recommended for children <1 year due to limited data.
Elderly: Lower initial doses (0.3-0.5 mcg/kg/min) with slower titration; increased sensitivity to hypotension. Monitor for thiocyanate accumulation (normal renal function may decline with age).
Initiate at lower doses due to increased sensitivity: Sublingual: 0.15-0.3 mg; Transdermal: 0.2 mg/day patch; Intravenous: Start at 5 mcg/min, titrate slowly. Monitor for hypotension and syncope. Avoid sustained-release formulations due to prolonged half-life.
Sodium nitroprusside can cause excessive hypotension and cyanide toxicity. Continuous monitoring of blood pressure and cyanide/thiocyanate levels is required. Prolonged infusion or high doses increase risk of cyanide poisoning.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Risk of cyanide toxicity, especially with prolonged infusion or renal impairment,Thiocyanate toxicity with renal failure,Hypotension requiring continuous blood pressure monitoring,Methemoglobinemia (rare)
Hypotension (especially with volume depletion or diuretic therapy), reflex tachycardia, tolerance (intermittent dosing with nitrate-free interval recommended), abrupt discontinuation may cause angina rebound.
Pre-existing hypotension,Compensatory hypertension (e.g., coarctation of aorta),Leber's optic atrophy (cytochrome oxidase deficiency),Severe renal impairment,Congenital optic atrophy,Poorly compensated heart failure
Concomitant use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil), severe anemia, increased intracranial pressure, hypersensitivity to nitrates, acute myocardial infarction with low filling pressure.
No specific food interactions. Patients should avoid excessive vitamin B12 or sulfur-containing supplements due to theoretical risk of increased thiocyanate production.
Avoid alcohol consumption as it may exacerbate nitroglycerin-induced hypotension and vasodilation. No specific food interactions documented; however, patients should maintain adequate hydration. High-fat meals may delay absorption, but sublingual route minimizes this effect. Grapefruit juice has no known interaction.
Pregnancy Category C. Risk cannot be ruled out. Animal reproduction studies have not been conducted with sodium nitroprusside. It should only be used in pregnant women if the potential benefit justifies the potential risk to the fetus. Due to its vasodilatory effects and potential for maternal hypotension, fetal hypoxia may occur. Use during labor may cause uterine relaxation and prolonged labor.
FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: risk of fetal bradycardia, hypotension, and reduced uteroplacental perfusion; avoid near term due to risk of maternal hypotension and neonatal bradycardia.
It is unknown if sodium nitroprusside is excreted in human breast milk. The M/P ratio is not available. Due to the short half-life and rapid metabolism, exposure to the nursing infant is likely minimal, but caution is advised.
Not recommended during breastfeeding. No data on M/P ratio; minimal excretion into breast milk expected but safety not established. Potential for infant hypotension and bradycardia.
No specific dose adjustments are recommended based solely on pregnancy. However, due to increased plasma volume and cardiac output during pregnancy, the hemodynamic response may be altered. Start at the low end of the dosing range (0.3-0.5 mcg/kg/min) and titrate to effect. Shorter duration of therapy is advised to minimize the risk of cyanide accumulation.
No standard dose adjustment required for pregnancy; use lowest effective dose. Increased plasma volume may reduce response; titrate to effect. Avoid in severe preeclampsia or volume depletion.
Protect solution from light; wrap infusion set with opaque material. Use only in ICU setting with continuous blood pressure monitoring. Monitor for cyanide toxicity, especially with high doses (>2 mcg/kg/min) or renal impairment. Onset of action is immediate; titrate to effect every 5 minutes. Do not use for more than 48 hours to avoid thiocyanate accumulation. Administer via dedicated IV line; incompatible with many drugs.
GONITRO (nitroglycerin sublingual powder) is indicated for acute relief of angina pectoris. Administer one packet (0.4 mg or 0.8 mg) at onset of chest pain; may repeat every 5 minutes up to 3 doses. Ensure patient is seated or lying down to avoid hypotension. Do not confuse with oral spray; powder must be placed under tongue. Onset within 1-3 minutes. Common side effect: headache. Contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) within 24-48 hours due to severe hypotension. Monitor for orthostatic hypotension.
This medication is used to rapidly lower blood pressure in emergencies.,You will have continuous blood pressure monitoring; report any headache, dizziness, nausea, or palpitations.,The solution is light-sensitive; the IV bag and tubing are wrapped to protect it.,Inform your doctor if you have kidney or liver disease, or a history of cyanide poisoning.,Do not stop the infusion abruptly; blood pressure must be reduced gradually.
Take one packet at the first sign of chest pain. Empty the entire powder under your tongue and let it dissolve. Do not swallow or rinse with water.,If pain persists after 5 minutes, take a second packet. If still no relief after 5 more minutes, take a third and call 911.,Sit or lie down when taking this medication to prevent dizziness or fainting.,Avoid alcohol; it may worsen side effects like low blood pressure.,Do not use Viagra, Cialis, Levitra, or other erectile dysfunction drugs while on this medicine—serious drop in blood pressure can occur.,Headaches are common; do not stop taking the medication. Over-the-counter pain relievers may help.,Store packets at room temperature away from moisture and heat. Do not open until ready to use.
"Primidone, a barbiturate anticonvulsant, can potentiate the hypotensive effects of sodium nitroprusside, a direct vasodilator used in hypertensive emergencies. This interaction may lead to exaggerated reductions in blood pressure, increasing the risk of hypotension, syncope, and reflex tachycardia. Such additive hypotensive effects necessitate careful monitoring and dose adjustments to prevent adverse cardiovascular outcomes."
"Amlodipine, a dihydropyridine calcium channel blocker, causes peripheral vasodilation by inhibiting calcium influx into vascular smooth muscle cells. Nitroprusside, a direct vasodilator, releases nitric oxide which activates guanylyl cyclase, leading to increased cGMP and smooth muscle relaxation. Concomitant use can lead to additive hypotension, potentially resulting in dizziness, syncope, or cardiovascular collapse, especially in patients with compromised cardiac function or volume depletion."
"Concurrent use of nitroprusside and diclofenamide may lead to an exaggerated hypotensive response. Diclofenamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and electrolyte disturbances, which may potentiate the vasodilatory effects of nitroprusside, increasing the risk of severe hypotension and reflex tachycardia. This interaction is particularly hazardous in patients with compromised cerebral or coronary perfusion, as it may precipitate ischemic events."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM NITROPRUSSIDE vs GONITRO, answered by our medical review team.
SODIUM NITROPRUSSIDE is a Vasodilator that works by Sodium nitroprusside is a prodrug that releases nitric oxide (NO) in vascular smooth muscle cells, activating guanylate cyclase and increasing c GMP, leading to vasodilation of both arterial and venous vessels.. GONITRO is a Nitrate Vasodilator that works by Nitric oxide (NO) donor; activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM NITROPRUSSIDE and GONITRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM NITROPRUSSIDE is: Intravenous infusion: Initial 0.3-0.5 mcg/kg/min; titrate up to 10 mcg/kg/min, maximum 10 mcg/kg/min for up to 10 minutes. Usual therapeutic dose: 3 mcg/kg/min. Max cumulative dose: 3.5 mg/kg.. The standard adult dose of GONITRO is: Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM NITROPRUSSIDE and GONITRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM NITROPRUSSIDE is classified as Category C. Pregnancy Category C. Risk cannot be ruled out. Animal reproduction studies have not been conducted with sodium nitroprusside. It should only be used in pregnant women if the poten. GONITRO is classified as Category C. FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.